First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study

(2020) Emmanuel Monnet et al.   ANNALS OF THE RHEUMATIC DISEASES

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer

(2020) Shuhao Zhu et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Chemical Modification of Aptamers for Increased Binding Affinity in Diagnostic Applications: Current Status and Future Prospects

(2020) Jan P. Elskens et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction

(2020) Rafael Ramirez-Carracedo et al.   Biomolecules

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration

(2020) Glenn J. Jaffe et al.   OPHTHALMOLOGY

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

(2019) Michael Steurer et al.   HAEMATOLOGICA

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

(2018) Joop van Gerven et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models

(2018) Gerónimo Fernández et al.   MOLECULAR THERAPY

An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications

(2017) Evan N. Dunn et al.   Ophthalmic Surgery Lasers & Imaging Retina

Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects

(2016) M Boyce et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Biological Basis for Cardiac Repair After Myocardial Infarction

(2016) Sumanth D. Prabhu et al.   CIRCULATION RESEARCH

Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

(2016) E Monnet et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de Farmacovigilancia

(2016) Carmelo Aguirre et al.   MEDICINA CLINICA

Aptamers as targeted therapeutics: current potential and challenges

(2016) Jiehua Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics

(2015) Marina A Dobrovolskaia et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

(2014) Janos Szebeni   MOLECULAR IMMUNOLOGY

Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases

(2013) Takakuni Maki et al.   CNS & Neurological Disorders-Drug Targets

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

(2013) Jonathan E. Rosenberg et al.   INVESTIGATIONAL NEW DRUGS

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

(2012) M. E. GORCZYCA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

(2010) Todd W. Rice et al.   CRITICAL CARE MEDICINE

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

(2009) Mark Tidswell et al.   CRITICAL CARE MEDICINE